Facial Nerve Decompression Surgery Using bFGF-Impregnated Biodegradable Gelatin Hydrogel in Patients with Bell Palsy

被引:24
作者
Hato, Naohito [1 ]
Nota, Jumpei [1 ]
Komobuchi, Hayato [1 ]
Teraoka, Masato [1 ]
Yamada, Hiroyuki [1 ]
Gyo, Kiyofumi [1 ]
Yanagihara, Naoaki [1 ]
Tabata, Yasuhiko [2 ]
机构
[1] Ehime Univ, Sch Med, Dept Otolaryngol, Toon City, Ehime 7910295, Japan
[2] Kyoto Univ, Inst Frontier Med Sci, Dept Biomat, Kyoto, Japan
关键词
basic fibroblast growth factor; biodegradable hydrogel; drug delivery system; Bell palsy; neuronal regeneration; HERPES-SIMPLEX-VIRUS; TRANSMASTOID DECOMPRESSION; SURGICAL-MANAGEMENT;
D O I
10.1177/0194599811431661
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Objective. Basic fibroblast growth factor (bFGF) promotes the regeneration of denervated nerves. The aim of this study was to evaluate the regeneration-facilitating effects of novel facial nerve decompression surgery using bFGF in a gelatin hydrogel in patients with severe Bell palsy. Study Design. Prospective clinical study. Setting. Tertiary referral center. Subjects and Methods. Twenty patients with Bell palsy after more than 2 weeks following the onset of severe paralysis were treated with the new procedure. The facial nerve was decompressed between tympanic and mastoid segments via the mastoid. A bFGF-impregnated biodegradable gelatin hydrogel was placed around the exposed nerve. Regeneration of the facial nerve was evaluated by the House-Brackmann (H-B) grading system. The outcomes were compared with the authors' previous study, which reported outcomes of the patients who underwent conventional decompression surgery (n = 58) or conservative treatment (n = 43). Results. The complete recovery (H-B grade 1) rate of the novel surgery (75.0%) was significantly better than the rate of conventional surgery (44.8%) and conservative treatment (23.3%). Every patient in the novel decompression surgery group improved to H-B grade 2 or better even when undergone between 31 and 99 days after onset. Conclusion. Advantages of this decompression surgery are low risk of complications and long effective period after onset of the paralysis. To the authors' knowledge, this is the first clinical report of the efficacy of bFGF using a new drug delivery system in patients with severe Bell palsy.
引用
收藏
页码:641 / 646
页数:6
相关论文
共 24 条
[1]   BASIC FIBROBLAST GROWTH-FACTOR PREVENTS DEATH OF LESIONED CHOLINERGIC NEURONS INVIVO [J].
ANDERSON, KJ ;
DAM, D ;
LEE, S ;
COTMAN, CW .
NATURE, 1988, 332 (6162) :360-361
[2]  
Ballance C, 1932, J OTOLARYNGOL, V15, P1
[3]   HYPOTENSIVE ACTIVITY OF FIBROBLAST GROWTH-FACTOR [J].
CUEVAS, P ;
CARCELLER, F ;
ORTEGA, S ;
ZAZO, M ;
NIETO, I ;
GIMENEZGALLEGO, G .
SCIENCE, 1991, 254 (5035) :1208-1210
[4]  
FISCH U, 1972, ARCHIV OTOLARYNGOL, V95, P335
[5]  
FISCH U, 1981, ARCH OTOLARYNGOL, V107, P1
[6]   The surgical management of Bell's palsy: A review [J].
Friedman, RA .
AMERICAN JOURNAL OF OTOLOGY, 2000, 21 (01) :139-144
[7]   Basic fibroblast growth factor promotes extension of regenerating axons of peripheral nerve. In vivo experiments using a Schwann cell basal lamina tube model [J].
Fujimoto, E ;
Mizoguchi, A ;
Hanada, K ;
Yajima, M ;
Ide, C .
JOURNAL OF NEUROCYTOLOGY, 1997, 26 (08) :511-528
[8]   Surgical management of Bell's palsy [J].
Gantz, BJ ;
Rubinstein, JT ;
Gidley, P ;
Woodworth, GG .
LARYNGOSCOPE, 1999, 109 (08) :1177-1188
[9]   Efficacy of early treatment of Bell's palsy with oral acyclovir and prednisolone [J].
Hato, N ;
Matsumoto, S ;
Kisaki, H ;
Takahashi, H ;
Wakisaka, H ;
Honda, N ;
Gyo, K ;
Murakami, T ;
Yanagihara, N .
OTOLOGY & NEUROTOLOGY, 2003, 24 (06) :948-951
[10]   Steroid and antiviral treatment for Bell's palsy [J].
Hato, Naohito ;
Murakami, Shingo ;
Gyo, Kiyofumi .
LANCET, 2008, 371 (9627) :1818-1820